All News

In a phase 2 study of 24 patients with biliary cancer, Aliqopa in combination with Gemzar and chemotherapy led to a six-month progression-free survival rate of 51% with a median overall survival of 13.7 months.

COVID-19 has robbed us of the physical ways we remember important milestones on the cancer journey and the physical ways we need to mourn.

Some patients receiving opioids to treat cancer-related pain may be more susceptible than others to engage in non-medical opioid use.

Tecentriq with carboplatin and etoposide led to a median overall survival rate of 12.3 months versus 10.3 months in those assigned placebo, carboplatin and etoposide, although the death rate was high at a median follow-up of 22.9 months.

On social media, CURE® recently asked its readers to share what they wished people without cancer could understand about their experiences with the disease.

A cancer survivor writes about how he, like many, was blindsided by his diagnosis and what it was like to receive treatment for a rare disease: penile cancer.

Even after surgery for breast cancer women can still feel empowered and own their sense of self-worth.

Regular aspirin use may increase survival in patients with bladder and breast cancer.

At three years, overall survival in men with nonmetastatic, castration-resistant prostate cancer treated with Nubeqa was 83% compared with 77% in those who received placebo.

The National Comprehensive Cancer Network (NCCN) recommends that patients receiving active cancer treatment get the COVID-19 vaccine.

A simple quote reminds a cancer survivor of what is important for every one of us to remember.

Combination treatment with Opdivo and Yervoy may have better overall survival rates for patients with metastatic uveal melanoma.

CURE® compiled a roundup of several recent news and updates involving quality of life improvements that patients with cancer may have missed.

CURE® compiled a roundup of five recent pieces of COVID-19 news and updates that patients with cancer may have missed.

After a fast-track designation, the Food and Drug Administration approved the combination of Cabometyx and Opdivo in the firstline setting for patients with advanced or metastatic renal cell carcinoma.

The priority review will focus on retifanlimab for the treatment of certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who did not tolerate platinum-based chemotherapy. Currently, according to Incyte, there are no approved treatments for this patient population.

With a terminal illness of metastatic breast cancer, I qualify for Social Security Disability as the COVID-19 pandemic has retired me, but that isn't stopping me from achieving my life goals.

From a Marine veteran walking 8,500 miles over the last 24 years to raise cancer awareness and funds for treatment to researchers using cancer cells from a deceased osteosarcoma donor to help advance treatment, here’s what’s happening in the cancer landscape this week.

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

SWORD Performance Hydration is a natural drink that helps to hydrate and energize individuals, and could even assist with some toxicities that are a result from chemotherapy.

“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

It's important for cancer survivors to recognize the major milestones and anniversaries in their cancer journey. Even if it's an anniversary they didn't want.

This week on the “CURE® Talks Cancer” podcast, we spoke with Martha Raymond, of The Raymond Foundation, about how providers can ensure patient safety to increase trial enrollment during the COVID-19 pandemic, and what she and her colleagues are doing to provide better trial access to all patients with cancer.

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

Clinical trials may seem scary and challenging for patients with cancer, but in reality, they don’t have to be. Here is how talking to former patients on clinical trials can help.

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Appointment fatigue is a real thing for patients with cancer and even survivors, but there are ways to overcome it.